With scientific partners that include Northridge, Calif.-based Medicus Research, Weber State University and leading independent laboratories, XanGo continues to spearhead scientific exploration of the whole mangosteen fruit through a tiered approach on safety, standardization and efficacy.
In XanGo’s most recent independent research of the mangosteen completed in January 2009, promising peer-reviewed clinical trials by the UCLA School of Medicine’s Dr. Jay K. Udani have shown that XanGo® Juice reduces inflammation in obese subjects, which may be valuable in preventing the progression to diabetes and heart disease. This eight-week randomized, double-blind, placebo-controlled study included a pre-study two-week washout period. It evaluated the effect of multiple dosages of a proprietary mangostoeen juice on indicators of inflammation and antioxidant levels in obese patients with elevated C-reactive protein (CRP) levels.
Previous independent research sponsored by XanGo has demonstrated that the proprietary whole fruit formula in XanGo Juice leads to high levels of xanthone absorption while unnaturally elevated levels of xanthone consumption actually were shown to decrease absorption efficiency.
XanGo is intent on continuing to lead the worldwide market in mangosteen-based research and category-creating mangosteen-based products. Expect more research in the coming years that continues to validate existing claims about the mangosteen and further product extensions that broaden the benefits of the mangosteen to myriad oral, topical and other wellness applications.